Skip to main content

Advertisement

SpringerLink
Log in

Drug development train gathering steam

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Inhibitors of specific signaling molecules may provide future treatments for acute lymphocytic leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cortes, J.E. & Kantarjian, H.M. Acute lymphoblastic leukemia — a comprehensive review with emphasis on biology and therapy. Cancer 76, 2393–2417 (1995).

    Article  CAS  Google Scholar 

  2. Ihle, J.N. Cytokine receptor signaling. Nature 377, 591–594 (1995).

    Article  CAS  Google Scholar 

  3. Levitski, A. & Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science 267, 1782–1789 (1995).

    Article  Google Scholar 

  4. Meydan, N. et al. Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature 379, 645–648 (1996).

    Article  CAS  Google Scholar 

  5. Dvir, A. et al. The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers. J. Cell Biol. 113, 857–865 (1991).

    Article  CAS  Google Scholar 

  6. Kaur, G. et al. Tyrphostin induced growth inhibition: Correlation with effect on p210 bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 5, 213–222 (1994).

    Article  CAS  Google Scholar 

  7. Migone, T.S. et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269, 79–81 (1995).

    Article  CAS  Google Scholar 

  8. Danial, N.N., Pernis, A. & Rothman, P.B. Jak-STAT signaling induced by the v-abl oncogene. Science 269, 1875–1877 (1995).

    Article  CAS  Google Scholar 

  9. Karp, J.E. & Broder, S. New directions in molecular medicine. Cancer Res. 54, 653–665 (1994).

    CAS  PubMed  Google Scholar 

  10. Gibbs, J.B., Oliff, A. & Kohl, N.E. Farnesyl-transferase inhibitors. Ras research yields a potential cancer therapeutic. Cell 77, 175–178 (1994).

    Article  CAS  Google Scholar 

  11. James, G.L. et al. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 260, 1937–1942 (1993).

    Article  CAS  Google Scholar 

  12. Jones, R.J. et al. Bryostatin 1, a unique biologic response modifier: Anti-leukemic activity in vitro. Blood 75, 1319–1323 (1990).

    CAS  PubMed  Google Scholar 

  13. May, W.S. et al. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA 84, 8483–8487 (1987).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sealy Center for Oncology and Hematology, The University of Texas Medical Branch at Galveston, Galveston, Texas, 77555-1048, USA

    Takahiko Ito & W. Stratford May

Authors
  1. Takahiko Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Stratford May
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ito, T., May, W. Drug development train gathering steam. Nat Med 2, 403–404 (1996). https://doi.org/10.1038/nm0496-403

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0496-403

  • Springer Nature America, Inc.

Search

Navigation